Ketamine / KAPPending re-verificationHospital-route model

SOMA Scandinavia

Denmark

Treatment & access

  • Treatments offeredPsychedelic psychotherapy with MDMA · Psychedelic psychotherapy with psilocybin · Microdosing (informational) · Ketamine in psychedelic therapy (information page marked as forthcoming)
  • Access routeprivate_pay
  • Price informationPrices not published on the provider's website.
  • Websitehttps://soma-scandinavia.com

About this provider

SOMA Scandinavia is a Danish association (forening) working to spread knowledge of psychedelic psychotherapy in Denmark. It describes itself as one of the pioneers of psychedelic psychotherapy in the country, with therapists holding specialised further training in therapy using psychedelic substances. It offers only longer-term therapeutic courses, typically around four months, on the basis that sustained work is needed for deep and lasting change, and connects potential clients with psychedelic psychotherapists. The site presents information on MDMA and psilocybin therapy, microdosing, and the history, ethics, legislation and commercialisation of the field. It contributes to public debate on official approval of psychedelic psychotherapy in Denmark and to the training of therapists and to research networks.

Services & programs

  • Psychedelic psychotherapy (MDMA and psilocybin)Longer-term individual psychotherapy combining psychedelic medicine with a specialised form of psychotherapy, delivered over a course typically lasting around four months with weekly therapist contact throughout. Presented as potentially relevant for depression, stress and burnout, anxiety, PTSD and trauma, substance misuse, OCD, and palliative support for cancer patients. Not published
  • Microdosing informationInformational content on microdosing of psychedelic medicine. Not published
  • Ketamine in psychedelic therapyAn information page describing ketamine as the first psychedelic medicine approved in Denmark for the treatment of depression; the detailed page is marked as forthcoming. Not published

Programs & studies

ProgramKindStatus
SOMA Scandinavia association activities
Contributes to public debate on official approval of psychedelic psychotherapy in Denmark, connects potential clients with therapists, supports therapist training, and networks with researchers and practitioners in Denmark, Scandinavia, the EU and internationally.
Advocacy, education and networkingActive

Facilities & languages

  • LanguagesWebsite presented in Danish.
  • TeamPresented as an association whose therapists hold specialised further training in therapy with psychedelic substances; individual clinician names are not published on the site.

Common questions

How much does a course of psychedelic psychotherapy cost and what is included?

Prices are not published on the website. The provider states it offers only longer-term therapeutic courses, typically around four months, with weekly therapist contact throughout the course.

Is psychedelic psychotherapy publicly approved or covered in Denmark?

The association states that it contributes to the public debate about official approval of psychedelic psychotherapy in Denmark, indicating such therapy is not yet officially approved; it notes ketamine as the first psychedelic medicine approved in Denmark for the treatment of depression.

How do I get started or make contact?

The site provides an online contact form for questions about psychedelic psychotherapy and states the association establishes contact between potential clients and psychedelic psychotherapists. No direct email address or phone number is published.

How long does a course of treatment last?

Courses are described as relatively short but longer-term, typically lasting around four months, with contact with the therapist every week throughout the treatment.

What conditions is psychedelic therapy presented as addressing?

The site states that research at universities and hospitals worldwide has shown psychedelic therapy may help with depression, stress and burnout, anxiety, PTSD and trauma, substance misuse, OCD, and palliative care for cancer patients with existential distress.

Looking at alternatives? In Denmark, esketamine (Spravato) for treatment-resistant depression has been recommended by Medicinradet since November 2025 and is dispensed through hospital psychiatric services, while MDMA- and psilocybin-assisted therapies remain investigational and are not generally approved.

Verification

This record was verified previously and is awaiting its scheduled re-check against the registry.

Spotted an error? See our methodology for how records are checked and how to report a correction.